Mark Albertella

Mark Albertella

Company: Storm Therapeutics

Job title: Vice President, Translational Oncology

Bio:

• Expert in oncology drug discovery and development with 20 years experience in biotech and pharma industry in the UK, US and Europe• Track record of consistent delivery at multiple levels in discovery research:
o Nomination of multiple candidate drugs
o Led discovery and development of MIV-818 into the clinic
o Multiple new projects proposed and successful transitions to LO• Track record of delivery in clinical and translational research
o Clinical biomarker strategy and execution on multiple clinical oncology projects
o Scientific leadership of translational research supporting clinical projects• Initiated and run many successful external collaborations in UK, US and Europe to support discovery and development projects throughout career• Core member of in-licensing team leading to successful acquisition of two clinical assets• Deep understanding of cancer biology, drug discovery and development, encompassing target validation, assay development, in vitro and in vivo biology and translational and clinical research• Excellent communicator with strong scientific record of publications, patents and presentations at global scientific conferences• Project and matrix management co-ordinating inter-disciplinary teams on multiple sites, collaborators and external CROs• O-1 US Visa awarded for extraordinary ability in sciences (December 2008)Personal skills
• Passionate champion of projects with innovative approaches and problem-solving skills• Highly collaborative scientist with networking and influencing skills required for instigating and running multiple projects and external collaborations• Excellent verbal and written communication skills, presenting to senior management teams, advisory boards, external audiences and publishing in international scientific journals• Proven adaptability and demonstrated ability to rapidly contribute to new areas of research and development

Seminars:

Targeting cancer with first-in-class inhibitors of the RNA m6A methyltransferase METTL3 8:30 am

Introduction to RNA modifications, the role of METTL3 and the m6A modification on selected mRNA species Overview of our drug discovery efforts to identify potent and selective inhibitors of METTL3 Characterisation of potent, selective, bioavailable inhibitors of METTL3 in biochemical, biophysical and cellular assays Exploration of utility of METTL3 inhibitors in hematological and solid tumour…Read more

day: Virtual Conference Day

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.